These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9485092)

  • 1. A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis.
    Davis JC; Austin H; Boumpas D; Fleisher TA; Yarboro C; Larson A; Balow J; Klippel JH; Scott D
    Arthritis Rheum; 1998 Feb; 41(2):335-43. PubMed ID: 9485092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
    Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
    Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA
    Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
    Illei GG; Yarboro CH; Kuroiwa T; Schlimgen R; Austin HA; Tisdale JF; Chitkara P; Fleisher T; Klippel JH; Balow JE; Boumpas DT
    Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
    Marks SD; Patey S; Brogan PA; Hasson N; Pilkington C; Woo P; Tullus K
    Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
    Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
    Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
    Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus.
    Stafford FJ; Fleisher TA; Lee G; Brown M; Strand V; Austin HA; Balow JE; Klippel JH
    J Rheumatol; 1994 Nov; 21(11):2068-70. PubMed ID: 7532717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.
    Boumpas DT; Furie R; Manzi S; Illei GG; Wallace DJ; Balow JE; Vaishnaw A;
    Arthritis Rheum; 2003 Mar; 48(3):719-27. PubMed ID: 12632425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
    Tamimoto Y; Horiuchi T; Tsukamoto H; Otsuka J; Mitoma H; Kimoto Y; Nakashima H; Muta K; Abe Y; Kiyohara C; Ueda A; Nagasawa K; Yoshizawa S; Shimoda T; Harada M
    Rheumatology (Oxford); 2008 Jun; 47(6):821-7. PubMed ID: 18397955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M; Graninger WB; Steiner G; Smolen JS
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Patschan S; Dolff S; Kribben A; Dürig J; Patschan D; Wilde B; Specker C; Philipp T; Witzke O
    Clin Exp Immunol; 2006 Aug; 145(2):235-42. PubMed ID: 16879242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravenous cyclophosphamide in lupus nephritis: twenty years reducing dose].
    Frutos MA; Martín Gómez A; de Ramón E; Camps MT; Valera A; García I; Fernández Nebro A
    Nefrologia; 2007; 27(1):12-22. PubMed ID: 17402875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis.
    Chan RW; Lai FM; Li EK; Tam LS; Chow KM; Li PK; Szeto CC
    Nephrol Dial Transplant; 2006 Jun; 21(6):1534-40. PubMed ID: 16449281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
    Davis JC; Fessler BJ; Tassiulas IO; McInnes IB; Yarboro CH; Pillemer S; Wilder R; Fleisher TA; Klippel JH; Boumpas DT
    J Rheumatol; 1998 Sep; 25(9):1694-704. PubMed ID: 9733448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.